LFB S.A. - Product Pipeline Review - 2015
Summary
Global Markets Directs, LFB S.A. - Product Pipeline Review - 2015, provides an overview of the LFB S.A.s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of LFB S.A.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of LFB S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of LFB S.A.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the LFB S.A.s pipeline products
Reasons to buy
- Evaluate LFB S.A.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of LFB S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the LFB S.A.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of LFB S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of LFB S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of LFB S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
LFB S.A. Snapshot 5
LFB S.A. Overview 5
Key Information 5
Key Facts 5
LFB S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
LFB S.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
LFB S.A. - Pipeline Products Glance 12
LFB S.A. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
LFB S.A. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
LFB S.A. - Drug Profiles 15
ublituximab 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
fibrinogen concentrate (human) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
roledumab 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LFB S.A. - Pipeline Analysis 20
LFB S.A. - Pipeline Products by Target 20
LFB S.A. - Pipeline Products by Route of Administration 21
LFB S.A. - Pipeline Products by Molecule Type 22
LFB S.A. - Pipeline Products by Mechanism of Action 23
LFB S.A. - Recent Pipeline Updates 24
LFB S.A. - Dormant Projects 29
LFB S.A. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
fibrinogen concentrate (human) 30
LFB S.A. - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34
List Of Tables
LFB S.A., Key Information 5
LFB S.A., Key Facts 5
LFB S.A. - Pipeline by Indication, 2015 7
LFB S.A. - Pipeline by Stage of Development, 2015 8
LFB S.A. - Monotherapy Products in Pipeline, 2015 9
LFB S.A. - Out-Licensed Products in Pipeline, 2015 10
LFB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
LFB S.A. - Phase III, 2015 12
LFB S.A. - Phase II, 2015 13
LFB S.A. - Phase I, 2015 14
LFB S.A. - Pipeline by Target, 2015 20
LFB S.A. - Pipeline by Route of Administration, 2015 21
LFB S.A. - Pipeline by Molecule Type, 2015 22
LFB S.A. - Pipeline Products by Mechanism of Action, 2015 23
LFB S.A. - Recent Pipeline Updates, 2015 24
LFB S.A. - Dormant Developmental Projects,2015 29
LFB S.A. - Discontinued Pipeline Products, 2015 30
LFB S.A., Other Locations 31
LFB S.A., Subsidiaries 31
List Of Figures
LFB S.A. - Pipeline by Top 10 Indication, 2015 7
LFB S.A. - Pipeline by Stage of Development, 2015 8
LFB S.A. - Monotherapy Products in Pipeline, 2015 9
LFB S.A. - Pipeline by Top 10 Target, 2015 20
LFB S.A. - Pipeline by Top 10 Route of Administration, 2015 21
LFB S.A. - Pipeline by Top 10 Molecule Type, 2015 22
LFB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 23
